To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Phase 1 Not yet recruiting 46 enrolled Genentech, Inc.

NaSequentialOpen-labelTreatment

Summary

The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).

Timeline

Start: 2026-07-31
Primary completion: 2030-03-29
Completion: 2030-03-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cevostamab	Monoclonal antibody	—	Intravenous
Background	Tocilizumab	Monoclonal antibody	—	—

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Summary

Timeline

Drugs

Indications